DMAC vs EXC · $157.4M cap vs P/E 17, rev $23.03B
DiaMedica Therapeutics Inc (DMAC) versus Exelon Corporation (EXC) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Exelon Corporation (EXC) is a utilities - regulated electric company listed on NASDAQ.
DMAC does not have a complete income-statement cache yet.
Latest reported EXC revenue for 2024-12-31 was $23.03B. Net income was $2.46B. Revenue was up 6.0% from 2023-12-31 to 2024-12-31. EXC currently screens at market cap $47.33B and trailing P/E 16.8.
DMAC currently screens at market cap $157.4M. EXC currently screens at market cap $47.33B and trailing P/E 16.8.
Not investment advice. Open the DMAC and EXC stock pages for the full models.
Not investment advice.